Skip to main content
main-content

01.12.2014 | Original Research | Ausgabe 4/2014

Journal of Radiation Oncology 4/2014

Adjuvant radiotherapy after prostatectomy: have randomized clinical trials had any impact?

Zeitschrift:
Journal of Radiation Oncology > Ausgabe 4/2014
Autoren:
Aaron E. Wagner, Amol J. Ghia, Dennis C. Shrieve, Kristine E. Kokeny, William T. Lowrance, Jonathan D. Tward

Abstract

Objective

The objective was to evaluate if the release of randomized trials evaluating the impact of adjuvant radiotherapy after prostatectomy in high risk patients had any impact on national practice patterns in patients with at least two high risk features.

Methods

The SEER database was used to extract data for patients with a diagnosis of prostate adenocarcinoma from the years 2004–2010, and who underwent prostatectomy with pathologic features of both extracapsular extension (ECE) and positive margins. Adjuvant radiotherapy (ART) utilization was calculated on a yearly basis, and odds ratios were calculated for the likelihood of ART use by year compared to 2004.

Results

Between 2004 and 2010, 5,231 patients were identified who underwent prostatectomy with both ECE and positive margins, of which only 19 % received ART. ART utilization was 21, 20, 22, 20, 18, 18, and 15 % for the years 2004–2010, respectively. Odds ratios demonstrated that the likelihood of ART to be used compared to 2004 demonstrated a statistical decrease from 0.97 (95 % C.I. 0.76–1.25, p = 0.85) in 2005 to 0.67 (95 % C.I. 0.51–0.90, p < 0.01) in 2010. At the end of the study time period, patients with higher risk disease were more likely to receive ART, with differences noted in clinical T stage, pretreatment PSA, Gleason score, Gleason patterns, and D’Amico risk classification (largest p = 0.02).

Conclusion

The release of randomized controlled trials demonstrating clinical and survival benefits with ART use in high risk patients has failed to increase the utilization of ART, instead demonstrating decreased utilization. In light of recently published guidelines, future changes will be of interest.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med bestellen und 100 € sparen!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2014

Journal of Radiation Oncology 4/2014 Zur Ausgabe
  1. Sie können e.Med Radiologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise